Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;52(7):581-9.
doi: 10.1007/s12275-014-3630-2. Epub 2014 May 30.

Responses of Candida albicans to the human antimicrobial peptide LL-37

Affiliations

Responses of Candida albicans to the human antimicrobial peptide LL-37

Pei-Wen Tsai et al. J Microbiol. 2014 Jul.

Abstract

Candida albicans is amajor fungal pathogen in humans. Antimicrobial peptides (AMPs) are critical components of the innate immune response in vertebrates and represent the first line of defense against microbial infection. LL-37 is the only member of the human family of cathelicidin AMPs and is commonly expressed by various tissues and cells, including surfaces of epithelia. The candidacidal effects of LL-37 have been well documented, but the mechanisms by which LL-37 kills C. albicans are not completely understood. In this study, we examined the effects of LL-37 on cell wall and cellular responses in C. albicans. Using transmission electron microscopy, carbohydrate analyses, and staining for β-1,3-glucan, changing of C. albicans cell wall integrity was detected upon LL-37 treatment. In addition, LL-37 also affected cell wall architecture of the pathogen. Finally, DNA microarray analysis and quantitative PCR demonstrated that sub-lethal concentrations of LL-37 modulated the expression of genes with a variety of functions, including transporters, regulators for biological processes, response to stress or chemical stimulus, and pathogenesis. Together, LL-37 induces complex responses in C. albicans, making LL-37 a promising candidate for use as a therapeutic agent against fungal infections.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Microbiology (Reading). 2005 May;151(Pt 5):1577-1592 - PubMed
    1. Infect Immun. 2010 Apr;78(4):1426-36 - PubMed
    1. Clin Microbiol Rev. 2006 Jul;19(3):491-511 - PubMed
    1. Microbiol Mol Biol Rev. 2006 Jun;70(2):317-43 - PubMed
    1. J Invest Dermatol. 2001 Jul;117(1):91-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources